Hi, and welcome to a forum suited for respectful, in-depth discussions.
>It [MTX-180] is clearly demonstrating great success with triple digit growth. I am not sure if they will need more funds as GW pointed out, but I am sure that the headway BSD has made will continue. <
As I see it, the sales growth for the MTX-180 product line is now emerging from the bold-pioneer stage. Now, the less adventurous but income-driven early adopters are likely to be attracted. And, so forth. This situation is, IMO, a classic example of rapid market penetration by a new, break-thru product. And, I don’t mean to say that the relatively income-driven doctors do not also have desire and pride re curing people’s ills – just that they are not disposed to bold behavior.
>The real issue for bottom line growth was getting the machines out there, thus creating that ongoing revenue stream... It is happening and now we just wait (I am going to be adding as I wait) until the investors understand that this inevitably profitable. I have suggested and maintain that it will be after the 6 consecutive quarter of triple digit growth before the real investors hop on board, but I am not waiting for that to occur before adding to my position. Its go time right now!!! 2 down, 4 to go.<
Since I also expect a jump in sales for the “2000 series” products, I believe there will be additional strong impetus for investors to take notice. Profitable operation by the end of this FY is IMO fairly likely. And, I think the company is due for a big jump in publicity.
Also, many Phase III trials for the BSD-2000 series are nearing completion – some have completed, I believe. And, these have shown highly effective performance – so U.S. FDA approval is surely near. As you know, approvals in other countries were garnered for the BSD-2000 machines, quite some time ago. (Things like this need repeating, as very few people using the SI MB system are aware of the company and its products.)
What investors need to keep in mind is that BSD M has pioneered a whole new cancer therapy area, applicable to and highly effective/very safe for a wide range of tumor types – not just yet another drug (with limited efficacy and horrible side effects) for some specific cancer. |
